Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALLO-501 · 1 trial · 2 indications
Dose limiting toxicity is defined as protocol-defined ALLO-501-related adverse events with onset within 28 days following infusion
Dose-limiting toxicity is defined as protocol-defined ALLO-647-related adverse events with onset within 33 days following 1st infusion
| Arm | Type | Description |
|---|---|---|
| ALLO-647, ALLO-501 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALLO-501 | GENETIC | ALLO-501 is an allogeneic CAR T cell therapy targeting CD19 |
| ALLO-647 | BIOLOGICAL | ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
Inclusion Criteria: * Histological or cytological diagnosis of Large B-cell Lymphoma (LBCL) or Follicular Lymphoma. * Relapse or refractory disease after at least 2 lines of chemotherapy * At least 1 measurable lesion at time of screening. * Eastern Cooperative Oncology Group Performance Status of ...
ALLO-501 is an investigational allogeneic CAR T cell therapy being studied for the treatment of relapsed/refractory large B cell lymphoma and relapsed/refractory follicular lymphoma. It is a gene therapy developed by Allogene Therapeutics, Inc. (NASDAQ: ALLO) and is currently in Phase 1 clinical development.
ALLO-501 targets CD19, a protein expressed on B cells. It is an anti-CD19 allogeneic CAR T cell therapy, meaning it uses donor-derived T cells engineered to recognize and attack CD19-positive cancer cells. This mechanism is being evaluated in patients with relapsed/refractory large B cell lymphoma and follicular lymphoma.
ALLO-501 is being developed by Allogene Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ALLO. The company is focused on developing allogeneic CAR T cell therapies for cancer treatment.
ALLO-501 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The drug has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which is intended to expedite the development and review of regenerative medicine therapies.
ALLO-501 has been studied in one completed Phase 1 clinical trial, NCT03939026, which evaluated the safety and efficacy of ALLO-501 in adults with relapsed/refractory large B cell lymphoma or follicular lymphoma. The trial enrolled 50 participants in the United States and was not randomized or blinded.
Yes, ALLO-501 is an anti-CD19 allogeneic CAR T cell therapy. It is designed to target CD19, a protein found on B cells, and is being investigated for the treatment of certain B cell lymphomas. The therapy is distinct from autologous CAR T therapies because it uses donor-derived cells.